Department of Cell and Developmental Biology and Consortium for Mitochondrial Research, University College London (UCL), Gower Street, London WC1E 6BT, UK.
Department of Cell and Developmental Biology and Consortium for Mitochondrial Research, University College London (UCL), Gower Street, London WC1E 6BT, UK.
Trends Mol Med. 2017 Feb;23(2):116-134. doi: 10.1016/j.molmed.2016.12.003. Epub 2017 Jan 19.
Lysosomal storage disorders (LSDs) are rare inherited debilitating and often fatal disorders. Caused by mutations affecting lysosomal proteins, LSDs are characterized by the accumulation of undegraded material in lysosomes and by lysosomal dysfunction. Although LSDs are multisystemic diseases, the majority display neurologic symptoms and neurodegeneration. Only recently has a role emerged for mitochondrial dysfunction in the pathophysiology of LSDs, suggesting an impact of lysosomal dysfunction on mitochondria. Moreover, mitochondrial damage may also cause lysosomal dysfunction, further supporting the activity of common signaling pathways and crosstalk between the two organelles. In this review we explore the mechanisms linking lysosomal and mitochondrial dysfunction to assess whether specific mitochondrial pathways represent a new therapeutic frontier in the management of LSDs.
溶酶体贮积症(LSDs)是罕见的遗传性进行性疾病,常导致死亡。由于影响溶酶体蛋白的突变引起,LSDs 的特征是溶酶体中未降解物质的积累和溶酶体功能障碍。尽管 LSDs 是多系统疾病,但大多数表现为神经症状和神经退行性变。直到最近,线粒体功能障碍在 LSDs 的病理生理学中的作用才显现出来,这表明溶酶体功能障碍对线粒体有影响。此外,线粒体损伤也可能导致溶酶体功能障碍,进一步支持这两个细胞器之间共同信号通路和串扰的活性。在这篇综述中,我们探讨了将溶酶体和线粒体功能障碍联系起来的机制,以评估特定的线粒体途径是否代表 LSDs 治疗的新前沿。